
港股生物医药股多数走低,君实生物跌超7%,药明康德跌超5%,药明生物、药明合联、再鼎医药、金斯瑞生物科技跌超4%。
东吴医药朱国广团队认为,中国的CRO/CDMO仍将持续具备全球竞争力,国际化分工与全球医药供应链的趋势难以因短期关税政策逆转。而原料药方面,美国深度依赖中国原料药供应,中短期无法脱钩。医疗器械方面,关税影响较小,看好内需国产替代+自主可控。
本文地址: http://www.jiaotongmi.com/article/18035.html
文章来源:admin
版权声明:除非特别标注,否则均为本站原创文章,转载时请以链接形式注明文章出处。
2025-11-09admin
2025-11-08admin
2025-11-07admin
2025-11-06admin
2025-11-05admin
2025-11-04admin
2025-11-03admin
2025-10-29admin
2025-10-29admin
2025-10-29admin
2025-09-08admin
2025-09-13admin
2025-09-17admin
2025-09-08admin
2025-09-17admin
2025-09-08admin
2025-09-09admin
2025-09-09admin
2025-09-13admin
2025-09-11admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-09admin
2025-09-08admin
2025-09-18admin
2025-09-08admin
2025-09-11admin
2025-09-08admin
2025-09-13admin
扫码二维码
获取最新动态
